Cargando…
Serologic status and safety of inactivated Covid‐19 vaccine for hepatocellular carcinoma patients with cirrhosis after curative liver resection
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9880698/ https://www.ncbi.nlm.nih.gov/pubmed/36566347 http://dx.doi.org/10.1002/cac2.12398 |
| _version_ | 1784878960076652544 |
|---|---|
| author | Liu, Fuchen Feng, Xiaochen Du, Jin Ruan, Minghao Liu, Hui |
| author_facet | Liu, Fuchen Feng, Xiaochen Du, Jin Ruan, Minghao Liu, Hui |
| author_sort | Liu, Fuchen |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9880698 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-98806982023-01-27 Serologic status and safety of inactivated Covid‐19 vaccine for hepatocellular carcinoma patients with cirrhosis after curative liver resection Liu, Fuchen Feng, Xiaochen Du, Jin Ruan, Minghao Liu, Hui Cancer Commun (Lond) Letters to the Editor John Wiley and Sons Inc. 2022-12-24 /pmc/articles/PMC9880698/ /pubmed/36566347 http://dx.doi.org/10.1002/cac2.12398 Text en © 2022 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat‐sen University Cancer Center. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| spellingShingle | Letters to the Editor Liu, Fuchen Feng, Xiaochen Du, Jin Ruan, Minghao Liu, Hui Serologic status and safety of inactivated Covid‐19 vaccine for hepatocellular carcinoma patients with cirrhosis after curative liver resection |
| title | Serologic status and safety of inactivated Covid‐19 vaccine for hepatocellular carcinoma patients with cirrhosis after curative liver resection |
| title_full | Serologic status and safety of inactivated Covid‐19 vaccine for hepatocellular carcinoma patients with cirrhosis after curative liver resection |
| title_fullStr | Serologic status and safety of inactivated Covid‐19 vaccine for hepatocellular carcinoma patients with cirrhosis after curative liver resection |
| title_full_unstemmed | Serologic status and safety of inactivated Covid‐19 vaccine for hepatocellular carcinoma patients with cirrhosis after curative liver resection |
| title_short | Serologic status and safety of inactivated Covid‐19 vaccine for hepatocellular carcinoma patients with cirrhosis after curative liver resection |
| title_sort | serologic status and safety of inactivated covid‐19 vaccine for hepatocellular carcinoma patients with cirrhosis after curative liver resection |
| topic | Letters to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9880698/ https://www.ncbi.nlm.nih.gov/pubmed/36566347 http://dx.doi.org/10.1002/cac2.12398 |
| work_keys_str_mv | AT liufuchen serologicstatusandsafetyofinactivatedcovid19vaccineforhepatocellularcarcinomapatientswithcirrhosisaftercurativeliverresection AT fengxiaochen serologicstatusandsafetyofinactivatedcovid19vaccineforhepatocellularcarcinomapatientswithcirrhosisaftercurativeliverresection AT dujin serologicstatusandsafetyofinactivatedcovid19vaccineforhepatocellularcarcinomapatientswithcirrhosisaftercurativeliverresection AT ruanminghao serologicstatusandsafetyofinactivatedcovid19vaccineforhepatocellularcarcinomapatientswithcirrhosisaftercurativeliverresection AT liuhui serologicstatusandsafetyofinactivatedcovid19vaccineforhepatocellularcarcinomapatientswithcirrhosisaftercurativeliverresection |